Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Celltech Group (NYSE: CLL) -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (7)	3/22/2000 10:03:00 AM
From: nigel bates	Read Replies (1) \| Respond to of 123

Minor munch - biz.yahoo.com Cistron and Celltech Sign Merger Agreement PINE BROOK, N.J., March 22 /PRNewswire/ -- Celltech Group, plc (NYSE: CLL - news; LSE: CCH), a major European-based biopharmaceutical company, and Cistron Biotechnology, Inc. (OTC Bulletin Board: CIST - news) located here have signed a merger agreement in which Cistron will become a wholly-owned subsidiary of Celltech. Under the agreement, Celltech will purchase Cistron for $18 million. This includes $8.75 million for intellectual property encompassing anti-interleukin (IL-1) antibodies as treatments for chronic inflammatory disorders and about $9.25 million for Cistron's cash reserves. nig